NDAORALTABLET
Approved
Oct 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ONFI (clobazam) by Lundbeck is cytochrome p450 2d6 inhibitors [moa]. Approved for epilepsy, dravet syndrome, lennox-gastaut syndrome and 1 more indications. First approved in 2011.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONFI (clobazam) is an oral benzodiazepine that inhibits cytochrome P450 2D6, used to treat refractory epilepsy including Dravet Syndrome and Lennox-Gastaut Syndrome. It is indicated as adjunctive therapy for seizure control in patients with these rare, treatment-resistant epilepsy types. The drug works through GABAergic mechanisms typical of benzodiazepines, enhancing inhibitory neurotransmission in the central nervous system.
Peak
ONFI is in peak lifecycle stage with moderate competitive pressure (30), suggesting stable market position but limited growth upside for commercial team expansion.
Mechanism of Action
Cytochrome P450 2D6 Inhibitors
Pharmacologic Class:
Benzodiazepine
Indications (4)
Worked on ONFI at Lundbeck? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.